Browse by author
Lookup NU author(s): John Hammond
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background/Aims: Transcatheter arterial chemoembolization (TACE) has been shown to increase survival in patients with unresectable hepatocellular carcinoma (HCC), however toxicity from commonly used agents limits its use in unresectable disease. Gemcitabine is a well tolerated chemotherapeutic agent with a high first pass clearance. In this study we evaluated a cohort of patients with unresectable HCC treated with gemcitabine-TACE alone. Methodology: A review of all patients that underwent gemcitabine-TACE for unresectable HCC from 2002 to 2006 was performed. No patients were eligible for resection, liver transplantation or ablation. All patients received gemcitabine-TACE alone. The primary outcome measure was survival from first treatment. Secondary outcome measures included radiological response and toxicity. Results: 55 patients underwent a total of 172 gemcitabine-TACE treatments for unresectable HCC. Median age was 64.7 years. All patients had Barcelona-Clinic Liver Cancer (BCLC) stage B (44%) or C (56%) disease. Median survival following gemcitabine-TACE was 8.8 months. 22% demonstrated a partial response and 61% had stable disease. 6% experienced grade 3/4 adverse events. There was 1 treatment related death. Conclusion: Gemcitabine-TACE is well tolerated and appears to provide an alternative agent for patients with unresectable HCC undergoing chemoembolization. © H.G.E. Update Medical Publishing S.A.
Author(s): Hammond JS, Franko J, Holloway SE, Heckman JT, Orons PD, Gamblin TC
Publication type: Article
Publication status: Published
Journal: Hepato-Gastroenterology
Year: 2014
Volume: 61
Issue: 133
Pages: 1339-1343
Online publication date: 01/07/2014
Acceptance date: 02/04/2014
ISSN (electronic): 0172-6390
Publisher: H.G.E. Update Medical Publishing Ltd.
URL: https://doi.org/10.5754/hge12720
DOI: 10.5754/hge12720
PubMed id: 25436307
Altmetrics provided by Altmetric
